Important regulatory notice. Tirzepatide (Mounjaro) is an MHRA-licensed prescription medicine in the United Kingdom. This page is a research-context summary of insulin-pathway pharmacology described in the published literature. It is not medical advice. Anyone taking tirzepatide should discuss any clinical question with their prescribing clinician.
Quick research summary. Tirzepatide is a dual GLP-1 and GIP receptor agonist. The published pharmacology literature describes its receptor binding and downstream effects on insulin secretion, glucagon biology and glycaemic regulation. The MHRA-approved Summary of Product Characteristics (SmPC) is the authoritative reference for the licensed UK clinical context.
The pharmacology in plain terms
Tirzepatide engages two incretin receptors: the GLP-1 receptor and the GIP receptor. Engagement of these receptors at the pancreatic beta-cell potentiates glucose-dependent insulin secretion. The ‘glucose-dependent’ part is important: the published mechanism describes amplification of insulin release in response to elevated glucose, which is biologically different from a constant insulin-pushing effect. The wider mechanistic picture also includes effects on glucagon biology and on appetite-regulating central pathways.
Where to read the regulator-grade clinical pharmacology
The MHRA-approved Summary of Product Characteristics for tirzepatide on the electronic Medicines Compendium (emc.medicines.org.uk) is the authoritative UK reference. The peer-reviewed pharmacology literature on tirzepatide and the wider GLP-1 / GIP class is indexed on PubMed.
If you are taking tirzepatide
Speak to your prescribing clinician about how the pharmacology applies to your specific clinical context. The Yellow Card Scheme at yellowcard.mhra.gov.uk is the UK reporting route for suspected adverse drug reactions.
Frequently Asked Questions
Is tirzepatide an insulin-secretion drug?
Tirzepatide is a dual GLP-1 / GIP receptor agonist. The published pharmacology describes glucose-dependent amplification of insulin secretion plus effects on glucagon and appetite biology.
Where is the authoritative pharmacology data?
The MHRA-approved Summary of Product Characteristics on emc.medicines.org.uk and the peer-reviewed pharmacology literature indexed on PubMed.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. We do not supply tirzepatide for human use; tirzepatide is a prescription-only medicine in the United Kingdom.
